MTNB - Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin | Benzinga
BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, will be featured in a fireside chat with David S. Perlin, PhD, a recognized expert in antifungals. The event is being sponsored by Alliance Global Partners (A.G.P.) and hosted by Scott Henry, A.G.P. Managing Director and Senior Research Analyst.
Topics of discussion will include an overview of the antifungal market and current treatment options, the clinical potential of MAT2203 as an oral formulation of amphotericin B, the market potential of MAT2203 and the design and key factors in the MAT2203 ORALTO pivotal trial in patients with invasive aspergillosis who have limited treatment options.
| Event: |
| Fireside Chat with Dr. David Perlin |
| Date: |
| June 18, 2024 |
| Time: |
| 4:00 p.m. Eastern time |
| Registration: |
| Participants can register to attend the event here. An archived webcast will be available for 60 days. |
Participants will have the opportunity to ask questions through the event platform.
Dr. David Perlin is the inaugural Chief Scientific Officer and Executive Vice President for the Hackensack Meridian Center for Discovery and Innovation, which seeks to rapidly translate innovations in science to improve outcomes for patients with cancer, infectious diseases, autoimmune and other acute and chronic disorders. He is an expert in drug discovery and drug-resistance mechanisms, and has helped develop novel therapeutics and diagnostics against high-threat bacteria, viruses and fungi. He has published more than 320 papers and book chapters, and has co-authored two books. The National Institutes of Health (NIH) has continuously funded his research for more than 30 years.
Dr. Perlin has served on advisory boards for the NIH, Bill & Melinda Gates Foundation, Global ...